Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Search ...
VBCN - November 2016 Volume 3, No 3
Simvastatin plus Vitamin D May Prevent Headaches in Adults with Migraines
By
Chase Doyle
Migraine
VBCN - November 2016 Volume 3, No 3
Results of a recent study have shown that simvastatin (Zocor) plus vitamin D is effective for the prevention of headache in adults with episodic migraine.
Read More
The Causes and Consequences of Misdiagnosing Multiple Sclerosis
By
Chase Doyle
Multiple Sclerosis
VBCN - November 2016 Volume 3, No 3
Despite improvements in radiographic diagnostic techniques, including magnetic resonance imaging (MRI), the misdiagnosis of multiple sclerosis (MS) is a common problem that can lead to treatment-related and psychosocial morbidity.
Read More
Alemtuzumab Reduces Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis
By
Laura Morgan
Multiple Sclerosis
VBCN - November 2016 Volume 3, No 3
A recent study investigated the effects of alemtuzumab (Lemtrada) on disability measures in patients with Multiple Sclerosis (MS).
Read More
Loss of Independence Common Even in Early-Stage Parkinson’s Disease
By
Charles Bankhead
Parkinson’s Disease
VBCN - November 2016 Volume 3, No 3
Nearly 3 times as many patients with newly diagnosed Parkinson’s disease had dependency in ≥1 activities of daily living (ADLs) compared with a healthy control group, a recent longitudinal, population-based study demonstrated.
Read More
One-Fourth of Eligible Patients with Stroke Still Not Receiving Thrombolytic Therapy
By
Charles Bankhead
Stroke
VBCN - November 2016 Volume 3, No 3
Despite a dramatic increase in the use of thrombolytic therapy for acute ischemic stroke, 25% of eligible patients still do not receive this treatment, according to data from a national registry.
Read More
FDA News - November 2016
FDA News
VBCN - November 2016 Volume 3, No 3
Abuse-Deterrent Troxyca ER Approved for Chronic Pain
Read More
Reducing the Cost and Improving the Care of Patients with Multiple Sclerosis
By
Laura Morgan
Multiple Sclerosis
VBCN - November 2016 Volume 3, No 3
The past 2 decades have seen significant improvements in disease-modifying therapies (DMTs) for multiple sclerosis (MS), and with them a surge in prices in the cost of therapy with sales more than doubling just in the past few years. As a result, there has been a significant rise in the cost of care for patients with MS.
Read More
In the Literature - November 2016
In the Literature
VBCN - November 2016 Volume 3, No 3
Sleep Disturbances Lead to Cognitive Decline
Alemtuzumab Demonstrates Superior Outcomes versus Interferon-ß-1a in Relapsing-Remitting Multiple Sclerosis
Aprepitant Relieves Nausea Associated with Dihydroergotamine Use for Migraine
Positive Effect of Hormone Therapy on Physical Function in Postmenopausal Women with Multiple Sclerosis
Read More
Stem-Cell Therapy Reverses Disability in Multiple Sclerosis
By
Laura Morgan
Multiple Sclerosis
VBCN - November 2016 Volume 3, No 3
Findings from an ongoing, phase 3 clinical trial involving patients with relapsing-remitting multiple sclerosis (MS) reveal that hematopoietic stem-cell transplantation (HSCT) may be a feasible treatment option for reversing disability associated with MS.
Read More
Timing of Epilepsy Onset Influences Type of Cognitive Impairment and Memory Deficits
By
Charles Bankhead
Epilepsy
VBCN - November 2016 Volume 3, No 3
Patients with early- versus late-onset epilepsy exhibited distinct differences in the origin of memory deficits, supporting the practice of subtyping patients by clinical characteristics to identify individualized predictors of cognitive dysfunction, according to the results of a new study.
Read More
Page 1 of 2
1
2
Search ...
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Subscribe to
Value-Based Care in Neurology
Stay up to date with personalized medicine by subscribing to recieve the free
VBCN
e‑Newsletter.
I'd like to recieve:
VBCN
e‑Newsletter
I have reviewed and consent to the terms of
VBCN
's
Privacy Policy
, and
VBCN
has my permission to retain my information in its database, and to forward pertinent communications to me.